Viral vectors for dendritic cell-based immunotherapy
L Jenne, G Schuler, A Steinkasserer - TRENDS in Immunology, 2001 - cell.com
L Jenne, G Schuler, A Steinkasserer
TRENDS in Immunology, 2001•cell.comTransduction of dendritic cells (DCs) by viral vectors genetically engineered to express
tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene
expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction
allows the control of DC quality, antigen quantity and site of DC reinjection. This review
evaluates the viral vectors currently being developed for use in DC-based immunotherapy.
tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene
expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction
allows the control of DC quality, antigen quantity and site of DC reinjection. This review
evaluates the viral vectors currently being developed for use in DC-based immunotherapy.
Abstract
Transduction of dendritic cells (DCs) by viral vectors genetically engineered to express tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction allows the control of DC quality, antigen quantity and site of DC reinjection. This review evaluates the viral vectors currently being developed for use in DC-based immunotherapy.
cell.com